Search
Menu
Home
HTB
2019
December
December 2019
Contents
Editorial
i-Base 2019 appeal: we need your help….
HTB 13 December 2019 online
Supplements
Introduction to ART – October 2019
UK Guide to PrEP – November 2019
Conference reports
17th European AIDS Conference (EACS 2019)
Capsid inhibitor GS-6207 (lenacapavir): potential for 6 monthly dosing for MDR HIV
Dolutegravir/lamivudine as dual ART
Weight changes with doravirine-based first line therapy
Bone and renal changes in the ADVANCE trial
10th International Workshop on HIV and Ageing
Impact of isolation and loneliness on older people living with HIV
Antiretrovirals
Doravirine approved by NHS England as single NNRTI and as part of FDC with 3TC/TDF
Fostemsavir submitted to US FDA for multidrug resistant HIV
Paediatric dispersible formulation of dolutegravir submitted to EMA and FDA
Weight, diabetes, metabolic complications
Tesamorelin for NAFLD in people living with HIV
PDFs
13 December 2019 vol 20 no 14
HTB RSS
Early access
The RIO study: Q&A about controlling HIV with bNAbs
21 April 2025
Lenacapavir EAP in the UK closed to new referrals: NHS England and Gilead fail to agree a price after more than two years
20 April 2025
Viral failure on CAB/RPV-LA: overcoming drug resistance with second-generation INSTIs
13 April 2025
Lancet HIV recognises Transgender Day of Visibility and the importance of gender-affirming hormones in HIV care
3 April 2025
All early access reports
Current issues
April 2025
March 2025
February 2025
Back issues
Special report
Lancet HIV recognises Transgender Day of Visibility and the importance of gender-affirming hormones in HIV care
3 April 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate